Expression of Concern: Splenda Alters Gut Microflora and Increases Intestinal P-Glycoprotein and Cytochrome P-450 in Male Rats (Journal of Toxicology and Environmental Health, Part A, (2008), 71, (1415-1429), 10.1080/15287390802328630);Splenda alters gut microflora and increases intestinal P-glycoprotein and cytochrome P-450 in male rats

Journal of Toxicology and Environmental Health - Part A: Current Issues

Volumn 71, Issue 21, 2008, Pages 1415-1429

  Abou Donia, Mohamed B ^a   El Masry, Eman M ^a   Abdel Rahman, Ali A ^a   McLendon, Roger E ^a   Schiffman, Susan S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2D1; CYTOCHROME P450 3A4; GLYCOPROTEIN P; SPLENDA; SUCRALOSE; SWEETENING AGENT; UNCLASSIFIED DRUG;

ANAEROBE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTEROIDES; BIFIDOBACTERIACEAE; BIOAVAILABILITY; CLOSTRIDIA; CONTROLLED STUDY; ENTEROBACTERIACEAE; ENZYME METABOLISM; FECES ANALYSIS; FOOD AND DRUG ADMINISTRATION; LACTOBACILLUS CASEI; MALE; MICROFLORA; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPRAGUE DAWLEY RAT; UNITED STATES; WESTERN BLOTTING;

ANIMALIA; BACTERIA (MICROORGANISMS); BACTEROIDES; CLOSTRIDIA; ENTEROBACTERIACEAE; RATTUS;

EID: 52149107761     PISSN: 15287394     EISSN: 10872620     Source Type: Journal    
DOI: 10.1080/15287394.2024.2321747     Document Type: Erratum

References (79)

1. Abou-Donia, M. B., El-Masry, E. M. and Abou-Qare, A. W. 2001. Metabolism and toxicokinetics of xenobiotics. In CRC handbook of toxicology, 2nd ed., eds. M. J. Derelanko and M. A. Hollinger, pp. 757-821. Boca Raton, FL: CRC Press LLC.
2. Abu-Qare, A. W., El-Masry, E. M., and Abou-Donia, M. B. 2003. A role for P-glycoprotein in environmental toxicology. J. Toxicol. Environ. Health A 66:279-288.
3. Albert, M. J., Mathan, V. I., and Baker, S. J. 1980. Vitamin B12 synthesis by human small intestinal bacteria. Nature 283:781-782.
4. Asghar, L. F., and Chandran, S. 2006. Multiparticulate formulation approach to colon specific drug delivery: Current perspectives. J. Pharmacol. Pharm. Sci. 9:327-338.
5. Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C.F., and Gordon, J. I. 2004. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. USA 101:15718-15723.
6. Bain, L. J., and LeBlanc G. A. 1996. Interaction of structurally diverse pesticides with the human MDR1 gene product P-glycoprotein. Toxicol. Appl. Pharmacol. 141:288-298.
7. Bauer, T. M. 1998. The role of gut bacteria in drug metabolism. In Gut and the liver, eds. H. E. Blum, C. Bode, J. C. Bode, and R. B. Sartor, pp. 177-184. Hingham, MA: Kluwer Academic.
8. Beerens, H. 1990. An elective and selective isolation medium for Bifidobacterium spp. Lett. Appl. Microbiol. 11:155-157.
9. Bois, F., Beney, C., Boumendjel, A., Mariotte, A. M., Conseil, G., and Di Pietro, A. 1998. Halogenated chalcones with high-affinity binding to P-glycoprotein: Potential modulators of multidrug resistance. J. Med. Chem. 41:4161-4164.
10. Booth, D. A. 1994. Psychology of nutrition, pp. 56-57. London: Taylor & Francis.
11. Clarke, S. E., and Jones, B. C. 2002. Human cytochromes P450 and their role in metabolism-based drug-drug interactions. In Drug-drug interactions, ed. A. D. Rodrigues, pp. 55-88. New York: Marcel Dekker.
12. Crowther, J. S. 1971. Transport and storage of faeces for bacteriological examination. J. Appl. Bacteriol. 34:477-483.
13. Cummings, J. H., and Macfarlane, G. T. 1997. Role of intestinal bacteria in nutrient metabolism. J. Parenteral Enteral Nutr. 21:357-365.
14. Dudeja, P. K., Kode, A., Alnounou, M., Tyagi, S., Torania, S., Subramanian, V. S., and Said, H. M. 2001. Mechanism of folate transport across the human colonic basolateral membrane. Am. J. Physiol. Gastrointest. Liver Physiol. 281:G54-G60.
15. Dürr, D., Stieger, B., Kullak-Ublick, G. A., Rentsch, K. M., Steinert, H. C., Meier, P. J., and Fattinger, K. 2000. St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther. 68:598-604.
16. Eagling, V.A., Profit, L., and Back, D. J. 1999. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br. J. Clin. Pharmacol. 48:543-552.
17. El-Masry, E. M., and Abou-Donia, M. B. 2006. Interaction of pyridostigmine bromide and N,N-diethyl-m-toluamide alone and in combination with Pglycoprotein expressed in Escherichia coli leaky mutant. J. Toxicol. Environ. Health A 69:919-933.
18. El-Masry, E. M., and Abou-Donia, M. B. 2003. Reversal of P-glycoprotein expressed in Escherichia coli leaky mutant by ascorbic acid. Life Sci. 73:981-991.
19. Engfer, M. B., Stahl, B., Finke, B., Sawatzki, G. and Daniel, H. 2000. Human milk oligosaccharides are resistant to enzymatic hydrolysis in the upper gastrointestinal tract. Am. J. Clin. Nutr. 71:1589-1596.
20. Federal Register. 1998. Food additives permitted for direct addition to food for human, consumption: Sucralose. Food and Drug Administration, HHS, Final Rule April 3, 1998 (Volume 63, Number 64), Rules and Regulations, pp. 16417-16433, Department Of Health And Human Services, Food and Drug Administration, 21 CFR Part 172, Docket No. 87F-0086. http://www.cfsan.fda. gov/~lrd/fr980403.html
21. Fooks, L. J., and Gibson, G. R. 2002. Probiotics as modulators of the gut flora. Br. J. Nutr. 88:S39-S49.
22. Fukushima, Y., Kawata, Y., Hara, H., Terada, A., and Mitsuoka, T. 1998. Effect of a probiotic formula on intestinal immunoglobulin A production in healthy children. Int. J. Food Microbiol. 42:39-44.
23. Geick, A., Eichelbaum, M., and Burk, O. 2001. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 276:14581-14587.
24. Gill, H. S., and Guarner, F. 2004. Probiotics and human health: A clinical perspective. Postgrad. Med. J. 80:516-526.
25. Goldsmith, L. A. 2000. Acute and subchronic toxicity of sucralose. Food Chem. Toxicol. 38(Suppl. 2):S53-S69.
26. Gottesman, M. M., Fojo, T., and Bates, S. E. 2002. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat. Rev. Cancer 2:48-58.
27. Grice, H. C., and Goldsmith, L. A. 2000. Sucralose - An overview of the toxicity data. Food Chem. Toxicol. 38(Suppl. 2):S1-S6.
28. Hart, A. L., Stagg, A. J., Frame, M., Graffner, H., Glise, H., Falk, P., and Kamm, M. A. 2002. The role of the gut flora in health and disease, and its modification as therapy. Aliment Pharmacol. Ther. 16:1383-1393.
29. Hill, M. J. 1997. Intestinal flora and endogenous vitamin synthesis. Eur. J. Cancer Prevent. 6(Suppl. 1):S43-S45.
30. Hirsch, A., and Grinsted, E. 1954. Methods for the growth and enumeration of anaerobic spore-formers from cheese with observations on the effect of nisin. J. Dairy Res. 21:101-110.
31. Holdeman, L. V., Cato, E. P., and Moore, W. E. C. 1977. Anaerobe laboratory manual, 4th ed., Blacksburg VA: Virginia Polytechnic Institute and State University.
32. Holzapfel, W. H., Haberer, P., Snel, J., Schillinger, U., and Huis in't Veld, J. H. 1998. Overview of gut flora and probiotics. Int. J. Food Microbiol. 41:85-101.
33. Iida, A., Tomita, M., and Hayashi, M. 2005. Regional difference in P-glycoprotein function in rat intestine. Drug Metab. Pharmacokinet. 20:100-106.
34. International Food Information Council Foundation. 2004. Everything you need to know about sucralose. Washington, DC: IFIC. http://www.ific.org/ publications/brochures/upload/sucralosebrochure.pdf
35. Jacobs, M. N., Nolan, G. T., and Hood, S. R. 2005. Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol. Appl. Pharmacol. 209:123-133.
36. Jang, H. J., Kokrashvili, Z., Theodorakis, M. J., Carlson, O. D., Kim, B. J., Zhou, J., Kim, H. H., Xu, X., Chan, S. L., Juhaszova, M., Bernier, M., Mosinger, B., Margolskee, R. F., and Egan, J. M. 2007. Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc Natl. Acad. Sci. USA 104:15069-15074.
37. Kille, J. W., Tesh, J. M., McAnulty, P. A., Ross, F. W., Willoughby, C. R., Bailey, G. P., Wilby, O. K., and Tesh, S. A. 2000. Sucralose: Assessment of teratogenic potential in the rat and the rabbit. Food Chem. Toxicol. 38(Suppl. 2): S43-S52.
38. Kleessen, B., Bunke, H., Tovar, K., Noack, J., and Sawatzki, G. 1995. Influence of two infant formulas and human milk on the development of the faecal flora in newborn infants. Acta Paediatr. 84:1347-1356.
39. Kleessen, B., Stoof, G., Proll, J., Schmiedl, D., Noack, J., and Blaut, M. 1997. Feeding resistant starch affects fecal and cecal microflora and short-chain fatty acids in rats. J. Animal Sci. 75:2453-2462.
40. Kliewer, S. A. 2003. The nuclear pregnane X receptor regulates xenobiotic detoxification. J. Nutr. 133:2444S-2447S.
41. Labare, M. P., and Alexander, M. 1994. Microbial cometabolism of sucralose, a chlorinated disaccharide, in environmental samples. Appl. Microbiol. Biotechnol. 42:173-178.
42. Lanning, C. L., Fine, R. L., Sachs, C. W., Rao, U. S., Corcoran, J. J., and Abou-Donia, M. B. 1996. Chlorpyrifos oxon interacts with the mammalian multidrug resistance protein, P-glycoprotein. J. Toxicol. Environ. Health 47:395-407.
43. Laurenzana, E. M., Sorrels, S. L., and Owens, S. M. 1995. Antipeptide antibodies targeted against specific regions of rat CYP2D1 and human CYP2D6. Drug Metab. Dispos. 23:271-278.
44. Leslie, E. M., Deeley, R. G., and Cole, S. P. 2005. Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 204:216-237.
45. Ley, R. E., Turnbaugh, P. J., Klein, S. and Gordon, J. I. 2006. Microbial ecology: Human gut microbes associated with obesity. Nature 444:1022-1023.
46. Lin, J. H., and Yamazaki, M. 2003. Role of P-glycoprotein in pharmacokinetics: Clinical implications. Clin. Pharmacokinet. 42:59-98.
47. MacFaddin, J. F. 1985. Media for isolation-cultivation-identification- maintenance of medical bacteria, vol. 1. Baltimore, MD: Williams & Wilkins.
48. Macfarlane, G. T., Macfarlane, S., and Gibson, G. R. 1992. Synthesis and release of proteases by Bacteroides fragilis. Curr. Microbiol. 24:55-59.
49. Mann, S. W., Yuschak, M. M., Amyes, S. J. G., Aughton, P., and Finn, J. P. 2000. A carcinogenicity study of sucralose in the CD-1 mouse. Food Chem. Toxicol. 38(Suppl. 2): S91-S98.
50. +-glucose cotransporter 1. Proc Natl. Acad. Sci. USA 104:15075-15080.
51. Matheny, C. J., Lamb, M. W., Brouwer, K. L. R., and Pollack, G. M. 2001. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 21:778-796.
52. Medina-Diaz, I. M., Arteaga-Illan, G., de Leon, M. B., Cisneros, B., Sierra-Santoyo, A., Vega, L., Gonzalez, F. J., and Elizondo, G. 2007. Pregnane X receptor-dependent induction of the CYP3A4 gene by o,p′-1,1,1,- trichloro-2,2-bis (p-chlorophenyl)ethane. Drug Metab. Dispos. 35:95-102.
53. Mevissen-Verhage, E. A., Marcelis, J. H., de Vos, M. N., Harmsen-van Amerongen, W. C., and Verhoef, J. 1987. Bifidobacterium, Bacteroides, and Clostridium spp. in fecal samples from breast-fed and bottlefed infants with and without iron supplement. J. Clin. Microbiol. 25:285-289.
54. Michalets, E. L. 1998. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 18:84-112.
55. Miller, G. A. 1991. Sucralose. In Alternative sweeteners, 2nd ed., ed. L. O. Nabors and R. C. Gelardi, pp. 173-195. New York: Marcel Dekker.
56. Peppercorn, M. A., and Goldman P. 1972. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J. Pharmacol. Exp. Ther. 181:555-562.
57. Poet, T. S., Wu, H., Kousba, A. A., and Timchalk, C. 2003. In vitro rat hepatic and intestinal metabolism of the organophosphate pesticides chlorpyrifos and diazinon. Toxicol. Sci. 72:193-200.
58. Rath, H. C., Schultz, M., Freitag, R., Dieleman, L. A., Li, F., Linde, H.-J., Scholmerich, J., and Sartor, R. B. 2001. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect. Immun. 69:2277-2285.
59. Rendic, S., and Di Carlo, F. J. 1997. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29:413-580.
60. Roberts, A., Renwick, A. G., Sims, J., and Snodin, D. J. 2000. Sucralose metabolism and pharmacokinetics in man. Food Chem. Toxicol. 38(Suppl. 2):S31-S41.
61. Rogosa, M., Mitchell, J. A., and Wiseman, R. F. 1951. A selective medium for the isolation and enumeration of oral and fecal lactobacilli. J. Bacteriol. 62:132-133.
62. Sasaki, Y. F., Kawaguchi, S., Kamaya, A., Ohshita, M., Kabasawa, K., Iwama, K., Taniguchi, K., and Tsuda, S. 2002. The comet assay with 8 mouse organs: Results with 39 currently used food additives. Mutat. Res. 519:103-119.
63. Schiffman, S. S., and Gatlin, C. A. 1993. Sweeteners: State of knowledge review. Neurosci. Biobehav. Rev. 17:313-345.
64. Schiffman, S. S., Sattely-Miller, E. A., and Bishay, I. E. 2008. Sensory properties of neotame: Comparison with other sweeteners. In Sweetness and sweeteners: Biology, chemistry and psychophysics, eds. D. K. Weerasinghe and G. R. Dubois. ACS Symposium Series, pp. 511-529. Oxford University Press: USA.
65. Sharpe, M. E. 1960. Selective media for the isolation and enumeration of lactobacilli. Lab. Pract. 9:223-227.
66. Shearer, M. J. 1995. Vitamin K. Lancet 345:229-234.
67. Sims, J., Roberts, A., Daniel, J. W., and Renwick, A. G. 2000. The metabolic fate of sucralose in rats. Food Chem. Toxicol. 38(Suppl. 2):S115-S121.
68. Sutter, V. L., Citron, D. M., Edelstein, M. A. C., and Finegold, S. M. 1985. Wadsworth anaerobic bacteriology manual, 4th ed. Belmont, CA: Star.
69. Teitelbaum, J. E., and Walker, W. A. 2002. Nutritional impact of pre- and probiotics as protective gastrointestinal organisms. Annu. Rev. Nutr. 22:107-138.
70. Tomkins, L. M., and Wallace, A. D. 2007. Mechanisms of cytochrome p450 induction. J. Biochem. Mol. Toxicol. 21:176-181.
71. Topping, D. L., Illman, R. J., Clarke, J. M., Trimble, R. P., Jackson, K. A., and Marsono, Y. 1993. Dietary fat and fiber alter large bowel and portal venous volatile fatty acids and plasma cholesterol but not biliary steroids in pigs. J. Nutr. 123:133-143.
72. Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., and Gordon, J. I. 2006. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444:1027-1031.
73. Tzortzis, G., Goulas, A. K., and Gibson, G. R. 2005. Synthesis of prebiotic galactooligosaccharides using whole cells of a novel strain, Bifidobacterium bifidum NCIMB 41171. Appl, Microbiol. Biotechnol. 68:412-416.
74. Wacher, V. J., Silverman, J. A., Zhang, Y., and Benet, L. Z. 1998. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. 87:1322-1330.
75. Wallis, K. J. 1993. Sucralose: Features and benefits. Food Austr. 45:578-580.
76. Williams, R. E. O., Hill, M. J., and Drasar, B. S. 1971. The influence of intestinal bacteria on the absorption and metabolism of foreign compounds. J. Clin. Pathol. Suppl. (R. Coll. Pathol.) 5:125-129.
77. Wong, J. M., de Souza, R., Kendall, C. W., Emam, A., and Jenkins, D. J. 2006. Colonic health: fermentation and short chain fatty acids. J. Clin. Gastroenterol. 40:235-243.
78. Yatka, R. J., Broderick, K. B., Song, J. H., Zibell, S. E., and Urnezis, P. W. 1992. Polyvinyl acetate encapsulation of sucralose from solutions for use in chewing gum. United States Patent 5169657. Assignee Wm. Wrigley Jr. Company (Chicago).
79. Young, D. A., and Bowen, W. H. 1990. The influence of sucralose on bacterial metabolism. J. Dent. Res. 69:1480-1484.